Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/28/24
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024GlobeNewsWire • 03/21/24
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024GlobeNewsWire • 03/20/24
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan ExecutionGlobeNewsWire • 03/13/24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross ProceedsGlobeNewsWire • 02/22/24
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance UpdateGlobeNewsWire • 02/15/24
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act's No-Cost Contraceptive Coverage RequirementGlobeNewsWire • 12/12/23
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024Accesswire • 11/22/23
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/09/23
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023GlobeNewsWire • 10/26/23
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/04/23
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim GroupAccesswire • 09/28/23
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/05/23
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second QuarterAccesswire • 08/17/23
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/09/23
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023GlobeNewsWire • 07/26/23
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With AfaxysAccesswire • 07/19/23
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control PatchAccesswire • 07/05/23
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023Accesswire • 07/03/23